Ohm, going from several sources, this is what I've found for IncellDX ownership:

Shares:
Bruce and CarolPatterson : 5,025,000 shares (33%)
Jeffrey Beaty: 350,000 shares (2.3%)
Opko Health, Inc/ 4,371,750 (29%)
Bio-Reference Labs
https://www.marketwatch.com/investing/stock/o...d=14902131
https://incelldx.com/incelldx-content/uploads...-3-121.pdf
Park Lane Ventures ?????? (??%)
Total shares (approx): 15,075,000
Unaccounted for shares: 5,328,250 (35.7%)

---

Convertible Notes:
Phillip Harrison $200,000
Francesco Tosco $250,000
Glenn Eisenberg $100,000
Paul Hydok $100,000
Dwigen Misra $100,000
Finger Family Office LLC $1,000,000
Jeffrey Weiner $100,000
Total: $1,850,000

---

Warrants:
Opko Health 40,000



So, if in 2018 Opko took a $2.9M charge to write down their 29% investment in IncellDX...that means they basically took a 50% hit on their initial $6M investment made in 2012.

How does that affect the valuation of IncellDX?


2012 - https://incelldx.com/incelldx-content/uploads...-3-121.pdf

2018 - https://d1io3yog0oux5.cloudfront.net/_36ec510...+Links.pdf